Humacyte, Inc. (HUMA)
Health Care · Biotechnology / Regenerative Medicine · NASDAQ
Humacyte is a regenerative medicine company that has commercialized a bioengineered, acellular human blood vessel for treating vascular trauma, with a pipeline targeting dialysis and cardiovascular surgery.
What Humacyte, Inc. does
Humacyte is a commercial-stage biotechnology company that develops universally implantable, bioengineered human tissues. Its primary product, Symvess, is an acellular tissue-engineered vessel (ATEV) approved for use as a vascular conduit for extremity arterial injury. The company is also developing its ATEV technology for additional applications including arteriovenous (AV) access for hemodialysis, peripheral arterial disease, coronary artery bypass grafting (CABG), and potential future delivery of cellular therapies.
Recent developments
In May 2026, the company implemented a workforce reduction of approximately 45 employees to reduce operating expenses. The company also announced breakthrough Phase 3 results for its ATEV in dialysis access, with a supplemental BLA filing planned for the second half of 2026. Additionally, the FDA accepted an IND for its coronary tissue-engineered vessel (CTEV), with a Phase 2a study for CABG expected to commence in Q3 2026.
From Humacyte, Inc.'s filing of 2026-08-12.
Themes: regenerative medicine, vascular surgery, hemodialysis / AV access, vascular trauma, coronary artery bypass grafting (CABG), cell delivery systems
Fundamentals
- Price$0.406 as of 2026-10-20 close
- Market cap$113M as of 2026-08-10 (share count; price 2026-10-20)
- 1-year return-77.6% 2025-10-20 close $1.81 → 2026-10-20 close $0.406
- P/En/a negative earnings
- Net margin-2003.6% FY2025, SEC XBRL
- ROE-1313.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity1.16 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Beta2.41 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How HUMA compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $406000 | -$27M | -$37M | -$0.16 | -$22M† | $104000† |
| Q1 FY2026 2026-03-31 | $495000 | -$29M | -$18M | -$0.09 | -$25M | $175000 |
| Q4 FY2025 2025-12-31 | $467000† | -$31M† | -$25M† | -$0.15† | -$26M† | $39000† |
| Q3 FY2025 2025-09-30 | $753000 | -$24M | -$18M | -$0.11 | -$24M† | $49000† |
| Q2 FY2025 2025-06-30 | $301000 | -$30M | -$38M | -$0.24 | -$26M† | $568000† |
| Q1 FY2025 2025-03-31 | $517000 | -$23M | $39M | $0.28 | -$29M | $228000 |
| Q4 FY2024 2024-12-31 | — | -$28M† | -$21M† | -$0.16† | -$27M† | $63000† |
| Q3 FY2024 2024-09-30 | $0 | -$30M | -$39M | -$0.33 | -$23M† | $934000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$80M
- Total debt$36M borrowings only; leases excluded
- Net debt-$44M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Humacyte, Inc. looks technically
Humacyte, Inc. (HUMA) is trading 51.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 475 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 78.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 51.2% below its 200-day average, the long-term trend line — a long-term downtrend | -51.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.5562 | $0.5562 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.8325 | $0.8325 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 0.61. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 475 trading days ago — a "death cross", a bearish long-term signal | 475 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control | 36.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($0.337 to $0.534) — its "stochastic" reading is 35 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 35.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $1.90 | $1.90 |
|---|---|---|
| From the 52-week high | it is 78.6% below its 52-week high (its highest price of the past year) | -78.6% |
| Above the 52-week low | it is 20.5% above its 52-week low (its lowest price of the past year) | +20.5% |
| Below the 52-week high | it is 78.6% below its highest point of the past year | 78.6% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $17.45 (set on 2021-09-01) | $17.45 |
| Given back of the 52-week move | over the past year its closes ranged ($0.354 to $1.81), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.25 to $1.30. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.6% |
| From the all-time high | it is 97.7% below its all-time high | -97.7% |
| Nearest price level | it is trading 33.9% below a resistance level at $0.5435 — a price it turned at twice since 2026-03-30, most recently on 2026-09-15. Since 2024-10-21 it has 0 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +33.9% |
| All-time low | its lowest closing price on record is $0.337 (set on 2026-10-14) | $0.337 |
| Above the all-time low | it is 20.5% above its all-time low | +20.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0404 between its high and its low — about 10.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0404 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.33 and $0.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.33 – $0.47 – $0.61 |
| Typical daily range (% of price) | its price moves about 10.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.9% |
| Stretch from the 200-day average | it is trading 10.6 daily ranges below its 200-day average price (51.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.89× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.17 toward sell |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 2.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.2% |
|---|---|---|
| Open gap | it gapped 3.8% below the previous close 42 sessions ago and has not traded back through the level it left behind at 0.74 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.8% |
| Gap filled | a 2.2% gap down opened on 2026-10-20 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 31.7 percentage points (the stock lost 30.7% while the market gained 1.0%) | -31.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.7 percentage points (the stock lost 38.1% while the market gained 3.6%) | -41.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 49.5 percentage points (the stock lost 41.0% while the market gained 8.5%) | -49.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 92.1 percentage points (the stock lost 77.6% while the market gained 14.6%) | -92.1% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -33.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 50% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $0.8125 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -50.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 27% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.5533 — a volume-weighted average of daily closes over 49 sessions, not a true tick-by-tick VWAP. | -26.6% |
Price levels it has turned at before
HUMA last closed at $0.406 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 10 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.5435 | Resistance | 33.9% above the last close | turned there twice · 2026-03-30 to 2026-09-15 |
| $0.6117 | Resistance | 50.7% above the last close | turned there three times · 2026-06-26 to 2026-09-21 |
| $0.75 | Resistance | 84.7% above the last close | turned there twice · 2026-08-10 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $0.61.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 21 trading days, since 2026-09-22.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$1.63 range $0.5 – $4.00; median $1.13
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HUMA
- Consensus EPS estimate-$0.0825 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 from -$0.0825, on 2026-09-11, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial history of operating losses and negative cash flows, creating significant uncertainty about the company's ability to maintain operations without further financing.","Dependence on the successful adoption and commercialization of Symvess and future ATEV products to generate revenue.","Risk of stock delisting from Nasdaq if compliance with continued listing requirements cannot be maintained."]
What changed in the latest 10-Q
AI-assisted comparison of HUMA's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-12) states: 'In June 2026, we announced positive interim results from our V012 Phase 3 trial in women, showing that the ATEV achieved superior catheter-free days compared to AV fistula, the primary endpoint in the study.' This disclosure of actual announced positive interim results is not present in the older filing (2026-05-13).
- Newer filing (2026-08-12) adds the full name 'coronary artery bypass grafting ("CABG")' in the ATEV development sentence, whereas the older filing used only the abbreviation 'CABG'.
- Removed:
- Older filing (2026-05-13) contains the sentence: 'In April 2023, we announced completion of enrollment of our V007 Phase 3 trial of the ATEV for use in AV access for hemodialysis.' This sentence is absent from the newer filing (2026-08-12).
- Older filing (2026-05-13) contains the conditional phrasing: 'If the interim results from our ongoing V012 Phase 3 trial in women are positive, we plan to submit a supplemental BLA...' This conditional statement is absent from the newer filing (2026-08-12).
- Reworded:
- Newer filing (2026-08-12) refers to the '"Forward-Looking Statements"' section; older filing (2026-05-13) refers to the '"Information Regarding Forward-Looking Statements"' section.
- Newer filing (2026-08-12) states Fresenius royalties will be paid to 'Fresenius Medical Care'; older filing (2026-05-13) states royalties will be paid to 'Fresenius'.
- Newer filing (2026-08-12) replaces the older filing's conditional statement about V012 interim results and the supplemental BLA plan with a definitive statement: 'We plan to submit a supplemental BLA for the ATEV to the FDA for an indication in AV access for hemodialysis in the second half of 2026,' and moves the V012 positive interim results announcement to the preceding sentence.
- Notes:
- The newer filing text ends mid-sentence ('United States at rates ranging from mid-single digits'), so comparison after that point is not possible.
- The older filing text also ends mid-sentence ('Fresenius remains obligated t'), so comparison after that point is not possible.
Risk Factors
- Added:
- Newer filing (2026-08-12) adds a new nasdaq delisting notice dated July 31, 2026, replacing the earlier May 4, 2026 notice.
- Newer filing (2026-08-12) adds that the compliance deadline is January 27, 2027 (180 calendar days from July 31, 2026).
- Newer filing (2026-08-12) adds disclosure under Item 2 about issuance of 240,000 warrants (Mayo Clinic Warrants) to Mayo Clinic at $1.11 per share.
- Newer filing (2026-08-12) adds disclosure about the Mayo Clinic Warrants vesting in three equal annual tranches of 80,000 shares on March 31, 2027, 2028, and 2029, expiring May 27, 2031.
- Newer filing (2026-08-12) adds a new exhibit 4.1 (Common Stock Purchase Warrant, dated May 27, 2026).
- Newer filing (2026-08-12) adds under Item 5 that Laura E. Niklason adopted a Rule 10b5-1 trading plan on June 3, 2026 for potential sale of up to 214,420 shares, with first possible trade date September 1, 2026 and termination by June 3, 2027.
- Removed:
- Older filing (2026-05-13) includes a 'Planned Reorganization' disclosure under Item 5 with estimates of approximately $0.8 million in aggregate severance charges and approximately $14.3 million in net savings during the remainder of 2026, which is removed in the newer filing.
- Reworded:
- Newer filing (2026-08-12) updates the reference period from 'three months ended March 31, 2026' to 'six months ended June 30, 2026' in the lead-in to the risk factors section.
- Newer filing (2026-08-12) changes the Nasdaq delisting facts: date of letter from May 4, 2026 to July 31, 2026; period end from May 1, 2026 to July 30, 2026; compliance deadline from November 2, 2026 to January 27, 2027.
- Newer filing (2026-08-12) removes the reference to Public Warrants de-listing risk that appeared in the older filing's delisting risk factor.
- Newer filing (2026-08-12) changes the phrasing 'The Nasdaq Stock Market LLC' in the older filing to 'Nasdaq' in the newer filing.
- Newer filing (2026-08-12) changes 'the bid price for the Company's Common Stock had closed below the minimum $1.00 per share requirement for continued listing' to 'the closing bid price of our Common Stock was below the minimum $1.00 per share requirement under Nasdaq Listing Rule 5450(a)(1)'.
- Newer filing (2026-08-12) changes 'The notice has no immediate effect' phrasing by removing 'This' and using 'The', and changes 'symbol' to 'the symbol'.
- Newer filing (2026-08-12) changes Item 2 from 'None' to disclosure of the Mayo Clinic Warrants issuance.
- Newer filing (2026-08-12) changes the Other Information trading arrangements paragraph from stating no director or officer adopted or terminated any plan during the three months ended March 31, 2026 to disclosing the Niklason 10b5-1 plan and stating no other director or officer adopted or terminated any plan during the three months ended June 30, 2026.
- Newer filing (2026-08-12) changes the exhibit numbering to add exhibit 3.1 and 4.1, shifting the existing Third Amendment to Distribution Agreement to exhibit 10.1 (with a '+' symbol) and adding 31.1 and 31.2 certifications.
- Notes:
- The newer filing text appears truncated at the end of the Item 6 exhibit list and may not reflect the complete exhibit section. Comparison is limited to the text provided.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
3 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-163 buys ($30370) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-165 buys ($90209) · 2 sells ($82294) — 3 buying, 2 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HUMA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding HUMA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,439,907
- Reported value $7,366,904
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 1 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about HUMA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
HUMA had 29,399,293 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
HUMA had 10.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.31 days to cover at the same settlement.
- Reported short interest (shares) 29,399,293
- Short interest (% of shares outstanding) 10.6%
- Prior settlement (shares) 31,807,566
- Reported change -7.57%
- Days to cover (reported) 7.31
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- W. L. Gore & Associates (synthetic grafts)
- Bard Peripheral Vascular (BD) (synthetic grafts)
- Cook Medical (synthetic grafts)
- Terumo (synthetic grafts)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Humacyte, Inc. is found in…
Frequently asked questions
What does Humacyte, Inc. (HUMA) do?
Humacyte is a commercial-stage biotechnology company that develops universally implantable, bioengineered human tissues. Its primary product, Symvess, is an acellular tissue-engineered vessel (ATEV) approved for use as a vascular conduit for extremity arterial injury. The company is also developing its ATEV technology for additional applications including arteriovenous (AV) access for hemodialysis, peripheral arterial disease, coronary artery bypass grafting (CABG), and potential future…
What sector is Humacyte, Inc. (HUMA) in?
Humacyte, Inc. (HUMA) is classified in the Health Care sector. Its industry is Biotechnology / Regenerative Medicine. It trades on NASDAQ.
Who are Humacyte, Inc.'s (HUMA) competitors?
Notable peers of Humacyte, Inc. (HUMA) include W. L. Gore & Associates (synthetic grafts), Bard Peripheral Vascular (BD) (synthetic grafts), Cook Medical (synthetic grafts) and Terumo (synthetic grafts). This peer set is informational only — not financial advice.
Is Humacyte, Inc. (HUMA) overbought or oversold right now?
Humacyte, Inc. (HUMA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HUMA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.